CA2393004A1 - Method of diagnosing neurodegenerative disease - Google Patents

Method of diagnosing neurodegenerative disease Download PDF

Info

Publication number
CA2393004A1
CA2393004A1 CA002393004A CA2393004A CA2393004A1 CA 2393004 A1 CA2393004 A1 CA 2393004A1 CA 002393004 A CA002393004 A CA 002393004A CA 2393004 A CA2393004 A CA 2393004A CA 2393004 A1 CA2393004 A1 CA 2393004A1
Authority
CA
Canada
Prior art keywords
alpha
test sample
acetylcholine receptor
nicotinic acetylcholine
receptor protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393004A
Other languages
French (fr)
Inventor
Daniel H. S. Lee
Allen B. Reitz
Carlos R. Plata-Salaman
Hoau-Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393004A1 publication Critical patent/CA2393004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods for diagnosing neurodegenerative disease such as Alzheimer's disease, monitoring the progression and prognosis of the disease and/or monitoring the therapeutic efficacy of any intervention or treatment of the disease comprising measuring the level of .alpha.7 nicotinic acetylcholine receptor protein.

Description

METHOD

Claims (11)

WHAT IS CLAIMED IS:
1. A method of diagnosis, determining prognosis, progression, or monitoring therapeutic efficacy of any intervention or treatment of neurodegenerative disease comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing .alpha.7 nicotinic acetylcholine receptor protein;
(b) contacting the test sample with a compound capable of specific interaction with the .alpha.7 nicotinic acetylcholine receptor protein; and (c) measuring the binding of the compound to .alpha.7 nicotinic acetylcholine receptor protein as an indication of .alpha.7 nicotinic acetylcholine receptor protein in the test sample.
2. The method of claim 1 wherein the neurodegenerative disease is Alzheimer's disease.
3. The method of claim 1 wherein the compound is a labeled compound.
4. The method of claim 1, 2 or 3 further comprising adding a step (d) of comparing changes in the level of .alpha.7 nicotinic acetylcholine receptor protein in the test sample with a normal sample from a subject known to lack neurodegenerative disease.
5. The method of claim 1, 2 or 3 wherein the test sample comprises a cell selected from the group consisting of circulating lymphocytes, olfactory neuroepithelial neuronal cell bodies or their neuronal processes, and hippocampal cells.
6. The method of claim 1 or 2 wherein the compound is selected from the group consisting of A.beta.1-40 peptide, A.beta.1-42 peptide, A.beta.1-43 peptide, a monoclonal antibody, and a polyclonal antibody.
7. The method of claim 1, 2, or 3 wherein the change is a decrease in the level of the .alpha.7 nicotinic acetylcholine receptor protein.
8. A method of diagnosis, determining prognosis, progression, or monitoring the therapeutic efficacy of any intervention or treatment of Alzheimer's disease comprising:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell selected from the group consisting of circulating lymphocytes, olfactory neuroepithelial neuronal cell bodies or their neuronal processes, or hippocampal cells, said cell expressing .alpha.7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with an antibody capable of specific interaction with the .alpha.7 nicotinic acetylcholine receptor protein; and (c) measuring the binding of the antibody to the .alpha.7 nicotinic acetylcholine receptor protein as an indication of decreases in the level of .alpha.7 nicotinic acetylcholine receptor protein in the test sample.
9. The method of claim 8 further comprises adding a step (d) of comparing changes in the level of .alpha.7 acetylcholine receptor protein in the test sample with a normal sample, from a subject known to lack neurodegenerative and neurological diseases.
10. A method to detect intracellular .alpha.7 nicotinic acetylcholine receptor protein in an Alzheimer's Disease subject which comprises the steps:

(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing .alpha.7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with a membrane perforating agent;
(c) contacting the test sample with a labeled compound capable of specific interaction with the .alpha.7 nicotinic acetylcholine receptor; and (d) measuring the binding of the compound to .alpha.7 nicotinic acetylcholine receptor protein as an indication of .alpha.7 nicotinic acetylcholine receptor protein in the test sample.
11. An immunoassay method to detect .alpha.7 nicotinic acetylcholine receptor protein in an Alzheimer's Disease subject which comprises the steps:
(a) obtaining a test sample from a subject wherein the test sample comprises a cell, said cell expressing .alpha.7 nicotinic acetylcholine receptor protein in healthy individuals;
(b) contacting the test sample with a labeled antibody capable of specific interaction with the .alpha.7 nicotinic acetylcholine receptor, wherein the antibody becomes a bound antibody or an unbound antibody;
(c) removing the unbound antibody from the test sample; and (d) measuring the quantity of bound or unbound antibody to indicate changes in the level of .alpha.7 nicotinic acetylcholine receptor protein in the test sample.
CA002393004A 1999-12-01 2000-11-16 Method of diagnosing neurodegenerative disease Abandoned CA2393004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823899P 1999-12-01 1999-12-01
US60/168,238 1999-12-01
PCT/US2000/031467 WO2001040261A1 (en) 1999-12-01 2000-11-16 Method of diagnosing neurodegenerative disease

Publications (1)

Publication Number Publication Date
CA2393004A1 true CA2393004A1 (en) 2001-06-07

Family

ID=22610681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393004A Abandoned CA2393004A1 (en) 1999-12-01 2000-11-16 Method of diagnosing neurodegenerative disease

Country Status (5)

Country Link
EP (1) EP1233979A1 (en)
JP (1) JP2003530542A (en)
AU (1) AU1920401A (en)
CA (1) CA2393004A1 (en)
WO (1) WO2001040261A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569354B2 (en) 2008-11-19 2013-10-29 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8710227B2 (en) 2010-05-17 2014-04-29 Envivo Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004095031A1 (en) * 2003-04-24 2004-11-04 Universität Zürich Method of monitoring immunotherapy
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8436145B2 (en) 2008-12-04 2013-05-07 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to Beclin-1
EP2385071A1 (en) 2008-12-04 2011-11-09 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1
KR20130108586A (en) 2010-09-23 2013-10-04 애브비 인코포레이티드 Monohydrate of an azaadamantane derivative
EP2872899B1 (en) * 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
WO2020188051A1 (en) 2019-03-19 2020-09-24 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder
KR102246021B1 (en) * 2019-10-10 2021-04-29 연세대학교 산학협력단 A composition for diagnosing of fibrosis and using thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US8569354B2 (en) 2008-11-19 2013-10-29 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8642638B2 (en) 2008-11-19 2014-02-04 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8815933B2 (en) 2008-11-19 2014-08-26 Forum Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8710227B2 (en) 2010-05-17 2014-04-29 Envivo Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
WO2001040261A1 (en) 2001-06-07
EP1233979A1 (en) 2002-08-28
JP2003530542A (en) 2003-10-14
AU1920401A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
US6447989B1 (en) Kidney disease detection and treatment
US6589748B2 (en) Method for kidney disease detection and treatment
AU2015262399B2 (en) Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
CN106062563B (en) Biomarkers and methods for early diagnosis of alzheimer's disease
US20230243853A1 (en) Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
Ghanbari et al. Biochemical assay for AD7C‐NTP in urine as an Alzheimer's disease marker
WO2004001421A2 (en) Method for the diagnosis and differential diagnosis of neurological diseases
Marksteiner et al. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study
CA2393004A1 (en) Method of diagnosing neurodegenerative disease
JP2004530904A (en) Detection of kidney disease by protein profiling
CA2017832A1 (en) Diagnostic assay for alzheimer's disease
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
WO2010005387A1 (en) New method and biomarkers for the diagnosis of multiple sclerosis
US7105485B2 (en) HO-1 suppressor as a diagnostic and prognostic test for dementing diseases
JP4283812B2 (en) Diagnostic method of myasthenia gravis and its kit
WO2019242750A1 (en) Title of the invention protein biomarkers for nephropathy and applications thereof
WO2008031190A1 (en) Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases
EP1371986A1 (en) Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
WO2002022165A9 (en) Non-genetic based protein disease markers
US8394639B2 (en) Biomarkers for renal disease
JP2013253781A (en) Inspection method and determination kit of neurodegenerative disease
JP2023536162A (en) Post-translational modification of p53 as a marker in the diagnosis and prognosis of neurodegenerative diseases

Legal Events

Date Code Title Description
FZDE Discontinued